Last update 29 Jul 2025

PF-08046876

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms-
Action
inhibitors
Mechanism
ITGB6 inhibitors(integrin subunit beta 6 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenocarcinoma of EsophagusPhase 1-07 Aug 2025
Advanced Lung Non-Small Cell CarcinomaPhase 1-07 Aug 2025
Advanced Malignant Solid NeoplasmPhase 1-07 Aug 2025
Bladder CancerPhase 1-07 Aug 2025
Esophageal Squamous Cell CarcinomaPhase 1-07 Aug 2025
Gastroesophageal junction adenocarcinomaPhase 1-07 Aug 2025
Pancreatic adenocarcinomaPhase 1-07 Aug 2025
Squamous Cell Carcinoma of Head and NeckPhase 1-07 Aug 2025
Urothelial Carcinoma of the Urinary BladderPhase 1-07 Aug 2025
Non-Small Cell Lung CancerPreclinical
United States
28 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free